In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic syndromes (MDS) and the results of the Phase Ib/II clinical trial (NCT03072043) headed by the MDS Clinical Research Consortium, which showed promising response rates for the treatment of this condition with the mutant p53 activator APR-246 when given in combination with azacitidine. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Is there hope for treating TP53-mutated MDS?
